177 related articles for article (PubMed ID: 34797614)
1. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
Robinson JC
N Engl J Med; 2021 Nov; 385(22):2017-2019. PubMed ID: 34797614
[No Abstract] [Full Text] [Related]
2. Medicare Coverage of Aducanumab - Implications for State Budgets.
Sachs RE; Bagley N
N Engl J Med; 2021 Nov; 385(22):2019-2021. PubMed ID: 34797617
[No Abstract] [Full Text] [Related]
3. Using Medicare Prices - Toward Equity and Affordability in the ACA Marketplace.
Song Z
N Engl J Med; 2017 Dec; 377(24):2309-2311. PubMed ID: 29045802
[No Abstract] [Full Text] [Related]
4. Healthcare 'reform': deep cuts likely for Medicare providers.
Gatty B
Geriatrics; 1994 Sep; 49(9):54-6. PubMed ID: 8088560
[No Abstract] [Full Text] [Related]
5. Medicare and drug pricing.
Iglehart JK
N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
[No Abstract] [Full Text] [Related]
6. US health reform: a mixed bag for insurers and drug companies.
Furlow B
Lancet Oncol; 2010 May; 11(5):417-8. PubMed ID: 20449872
[No Abstract] [Full Text] [Related]
7. Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.
Moghavem N; Henderson VW; Greicius MD
Ann Neurol; 2021 Sep; 90(3):331-333. PubMed ID: 34278596
[No Abstract] [Full Text] [Related]
8. Healthcare Reform: State Specific Responses.
Patrick KC;
Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-35. PubMed ID: 28248476
[No Abstract] [Full Text] [Related]
9. Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?
Crosson FJ; Covinsky K; Redberg RF
JAMA Intern Med; 2021 Oct; 181(10):1278-1280. PubMed ID: 34254992
[No Abstract] [Full Text] [Related]
10. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Schulman KA; Greicius MD; Richman B
JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
[No Abstract] [Full Text] [Related]
11. The need for health care reform.
Mossinghoff GJ
Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
[No Abstract] [Full Text] [Related]
12. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
[No Abstract] [Full Text] [Related]
13. Will reference pricing address the health cost conundrum?
Iglehart JK
Health Aff (Millwood); 2003; 22(3):7-8. PubMed ID: 12757267
[No Abstract] [Full Text] [Related]
14. Modeling hospice changes to prepare for Medicare reimbursement and care delivery reform.
Caring; 2013 Sep; 32(7):26-7. PubMed ID: 24312972
[No Abstract] [Full Text] [Related]
15. [Not Available].
Watt JA; Marple R; Hemmelgarn B; Straus SE
CMAJ; 2021 Nov; 193(43):E1680-E1682. PubMed ID: 34725122
[No Abstract] [Full Text] [Related]
16. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
Silver J
JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
[No Abstract] [Full Text] [Related]
17. Undermining Value-Based Purchasing - Lessons from the Pharmaceutical Industry.
Dafny LS; Ody CJ; Schmitt MA
N Engl J Med; 2016 Nov; 375(21):2013-2015. PubMed ID: 27732125
[No Abstract] [Full Text] [Related]
18. Response to Achieving cost control, care coordination, and quality improvement through incremental payment system reform.
Bertko J
J Ambul Care Manage; 2010; 33(1):24-5; discussion 69-70. PubMed ID: 20026993
[No Abstract] [Full Text] [Related]
19. Comment on "Achieving cost control, care coordination, and quality improvement through incremental payment system reform".
Sweeney R; Ciccone K
J Ambul Care Manage; 2010; 33(1):58; discussion 69-70. PubMed ID: 20027000
[No Abstract] [Full Text] [Related]
20. Industry perspectives: ensuring vaccination of children and adolescents without financial barriers.
Feinberg MB; Gordon L
Pediatrics; 2009 Dec; 124 Suppl 5():S563-4. PubMed ID: 19948589
[No Abstract] [Full Text] [Related]
[Next] [New Search]
